GNT’s Multi-Target Stroke Drug Builds Hopes For Longer Window
This article was originally published in PharmAsia News
GNT Pharma is set to begin a Phase II clinical trial of the world's first multi-target stroke therapy Neu2000, which may propose a new treatment method for ischemic stroke patients who receive revascularization treatment. The South Korean drug developer plans to seek a global licensing out deal for the drug, which is said to sharply extend the time window for stroke treatment, based on the outcome of the study.
Register for our free email digests: